Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population.
about
The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical researchCorrelation between the Serum Pepsinogen I Level and the Symptom Degree in Proton Pump Inhibitor-Users Administered with a Probiotic.Gastric corpus atrophy in gastric cancer screenings: Benefits and drawbacks.Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Marked decrease in serum pepsinogen II levels resulting from endoscopic resection of a large duodenal tumor.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasRationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.Gastric acid hypersecretory states: recent insights and advances.High Serum Pepsinogen I and beta Helicobacter pylori Infection Are Risk Factors for Aspirin-Induced Gastroduodenal Injury.Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.Accuracy of the GastroPanel test in the detection of atrophic gastritis.Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis.Influence of endoscopic submucosal dissection on serum levels of pepsinogens in patients with early gastric cancer.
P2860
Q33921574-C046D666-52A9-40F9-9906-1DFF23877CDEQ33963101-F31491FB-A165-45D3-A13F-AA4F70D3ADA2Q34135025-142B1D75-9D1F-4FD9-9772-1EF83D776270Q34157385-BAEB88CC-0D36-4195-857F-1281951BDD06Q34664635-A8E3247B-8C88-424E-9E2F-539F4B1B7090Q35001777-12F1E048-9FD2-4E7A-9685-010FEAC17874Q35755917-185323C5-B2B6-4659-A9A9-105969778C3FQ36069062-0BEA47B8-B29E-4F4D-9567-7C3B15D4A96EQ36351873-690BA245-3FD5-4A9E-8595-A57B44DAF750Q37238180-74960AB0-C9B2-4613-95D1-13C1833B5AB9Q37474172-D54EEE08-7BFF-4715-B33C-A2A63940448DQ40180037-F767BCBD-A7FD-4C72-9FF0-16F64D7DEC7AQ40394526-31C9214E-FA8E-4AC1-96F6-C2D6B222EF4FQ43158948-586D0ECC-DEDB-4768-A0CE-61E2FFDF6867Q47985401-64CDE955-D72D-490F-8BC9-9089DAC2ED4DQ50916790-5B877613-4CC9-45E8-8834-B98490262899
P2860
Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Clinical use of proton-pump in ...... in a random adult population.
@en
Clinical use of proton-pump in ...... in a random adult population.
@nl
type
label
Clinical use of proton-pump in ...... in a random adult population.
@en
Clinical use of proton-pump in ...... in a random adult population.
@nl
prefLabel
Clinical use of proton-pump in ...... in a random adult population.
@en
Clinical use of proton-pump in ...... in a random adult population.
@nl
P2093
P2860
P1476
Clinical use of proton-pump in ...... in a random adult population.
@en
P2093
Jukka Ronkainen
Lars Agréus
Nicholas J Talley
Pentti Sipponen
Pertti Aro
Tom Storskrubb
P2860
P304
P356
10.1080/00365520902745062
P577
2009-01-01T00:00:00Z